Obinutuzumab in two patients suffering from immune-mediated thrombotic thrombocytopenic purpura intolerant to rituximab

Am J Hematol. 2019 Oct;94(10):E259-E261. doi: 10.1002/ajh.25583. Epub 2019 Aug 9.

Authors

Judith Robertz¹, Martin Andres¹, Behrouz Mansouri Taleghani¹, Irene Koneth², Isabelle Binet², Johanna A Kremer Hovinga^{1

3}

Affiliations

¹ Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
² Nephrology and Transplantation Medicine, Kantonsspital St. Gallen, Sankt Gallen, Switzerland.
³ Department for Biomedical Research, University of Bern, Bern, Switzerland.

PMID: 31321811
DOI: 10.1002/ajh.25583

No abstract available

Publication types

Case Reports
Letter
Research Support, Non-U.S. Gov't

MeSH terms

ADAMTS13 Protein / blood
ADAMTS13 Protein / deficiency
Adrenal Cortex Hormones / therapeutic use
Antibodies, Monoclonal, Humanized / therapeutic use*
Antigens, CD20 / immunology
Cholecystectomy
Cholecystitis / complications
Cholecystitis / surgery
Combined Modality Therapy
Consciousness Disorders / etiology
Drug Therapy, Combination
Female
Fetal Death / etiology
Histamine Antagonists / therapeutic use
Humans
Male
Middle Aged
Plasma Exchange
Postoperative Complications / etiology
Postoperative Hemorrhage / etiology
Pregnancy
Pregnancy Complications, Hematologic / drug therapy
Purpura, Thrombotic Thrombocytopenic / complications
Purpura, Thrombotic Thrombocytopenic / diagnosis
Purpura, Thrombotic Thrombocytopenic / drug therapy*
Purpura, Thrombotic Thrombocytopenic / therapy
Recurrence
Rheumatic Heart Disease / complications
Rituximab / administration & dosage
Rituximab / adverse effects
Seizures / etiology
Serum Sickness / etiology
Young Adult

Substances

Adrenal Cortex Hormones
Antibodies, Monoclonal, Humanized
Antigens, CD20
Histamine Antagonists
Rituximab
ADAMTS13 Protein
ADAMTS13 protein, human
obinutuzumab

Grants and funding